

# Neil Bailey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4219811/publications.pdf>

Version: 2024-02-01

24  
papers

736  
citations

1163117

8  
h-index

888059

17  
g-index

24  
all docs

24  
docs citations

24  
times ranked

1703  
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e435-e442.	0.4	6
2	Outcomes of Chronic Lymphocytic Leukemia and Richter Transformation Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors. <i>Blood</i> , 2021, 138, 2629-2629.	1.4	0
3	Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax. <i>Blood</i> , 2021, 138, 2628-2628.	1.4	10
4	Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>Blood</i> , 2021, 138, 165-165.	1.4	6
5	Awareness, Knowledge, and Preferences of United States (US) Patients with Chronic Lymphocytic Leukemia (CLL) and Their Caregivers Related to Finite Duration (FD) Therapy and Minimal (Measurable) Residual Disease (MRD). <i>Blood</i> , 2021, 138, 1927-1927.	1.4	0
6	Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study. <i>Blood</i> , 2021, 138, 529-529.	1.4	4
7	Initial Safety Results from a Phase II Study of Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 4554-4554.	1.4	0
8	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143.	1.4	248
9	Use of convalescent plasma in hospitalized patients with COVID-19: case series. <i>Blood</i> , 2020, 136, 759-762.	1.4	124
10	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	7.0	80
11	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. <i>Haematologica</i> , 2020, 106, 284-287.	3.5	8
12	A Phase 2, Open-Label, Multicenter Study of Tazemetostat in Combination with Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2020, 136, 4-4.	1.4	4
13	The Efficacy of Passive Valve Antimicrobial Swab Caps Against Existing Clabsi Prevention Bundle in an Adult Hematology Inpatient Population: A Quality Improvement Initiative. <i>Blood</i> , 2020, 136, 13-14.	1.4	0
14	Real World Observational Study Using Clonoseq® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry. <i>Blood</i> , 2020, 136, 37-37.	1.4	0
15	Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 34-34.	1.4	1
16	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	1.4	2
17	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019, 25, 4264-4270.	7.0	61
18	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573.	5.2	26

#	ARTICLE	IF	CITATIONS
19	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019, 134, 502-502.	1.4	4
20	Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients. <i>Blood</i> , 2019, 134, 4311-4311.	1.4	15
21	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018, 103, 1511-1517.	3.5	135
22	Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. <i>Blood</i> , 2018, 132, 3142-3142.	1.4	2
23	A Single Center Retrospective Study of Real World Relapsed/Refractory DLBCL Patients Eligible for CAR T-Cell Therapy: Patient Characteristics and Outcomes. <i>Blood</i> , 2018, 132, 1715-1715.	1.4	0
24	Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings. <i>Blood</i> , 2018, 132, 4410-4410.	1.4	0